Sometime in the next few months PHST should do what it has been waiting to do for five years.... complete its gigantic cup and handle pattern, one of the longest in duration I have ever seen.
I expect that the move through $2.50 could be magnificent in scale, to remain in sympathy with the previous PPS gyrations over time, 0.06 to $2.50 on the backside of the cup.
RECIPE 2:PHST -Desperately needs a visit from the Volume Fairy. PPS was at about $1.50 when first mentioned a few weeks ago. Now at $1.45. I'm considering an entry.
Here's what's hurting them: Revenue for the three months ended December 31, 2005 decreased approximately 11% to $5.8 million, compared to $6.5 million in the same period in fiscal 2005. The decrease was primarily attributable to a decrease in strategic consulting services revenue as we provided less services to our customers. Due to an unexpected downturn in the pharmaceutical industry, our customers and potential customers have recently reduced their spending on strategic consulting services. During the three months ended December 31, 2005, we were particularly affected by the decreased spending by one of our largest strategic consulting services customers.
Here's what might help them: Pharsight to Host Amsterdam Seminar on Technical Challenges in Modeling and Simulation to Support Critical Path Initiatives
Dr. Daniel Weiner Will Discuss 'Increasing the Strategic Value of Kinetic and Dynamic Data Through Unified Modeling, Higher Productivity, and Regulatory Compliance'
MOUNTAIN VIEW, Calif., March 24, 2006 /PRNewswire-FirstCall via COMTEX/ -- Pharsight Corporation (OTC Bulletin Board: PHST), a leading provider of software and strategic services for optimizing clinical drug development, announced today that Dan Weiner, Ph.D., Senior Vice President, Software, will speak to members of the pharmaceutical and biotechnology industries at a seminar on technical aspects of modeling and simulation as outlined in FDA's Critical Path on April 25, 2006 at 1:30 PM local (Amsterdam) time.
Dr. Weiner's presentation will discuss the evolution of FDA's view of the role of modeling and simulation in regulatory decisions and trial design; the IT infrastructure needed by commercial companies to support impactful, regulatory-compliant, high-productivity modeling and simulation; innovations in modeling and simulation software that will flatten the learning curve and improve modeling productivity, especially in mixed effects modeling. More information is available at http://www.pharsight.com/events/events_home.php .
harsight to Present at Insightful Life Sciences Event on March 24, 2006
Dr. Andreas Krause Will Speak in Basel, Switzerland on Principles and Structured Approaches in Clinical Data Graphics
MOUNTAIN VIEW, Calif., March 21, 2006 /PRNewswire-FirstCall via COMTEX/ -- Pharsight Corporation (OTC Bulletin Board: PHST), a leading provider of software and strategic services for optimizing clinical drug development, announced today that Andreas Krause, Ph.D., Senior Scientist, will speak to members of the European pharmaceutical industry attending the Insightful Life Sciences Event on Clinical Data Review and Reporting, to be held at the Hotel Victoria in Basel, Switzerland, on March 24, 2006.
Pharsight to Present in Japan at Modeling and Simulation Symposium on March 23, 2006
Dr. Yuying Gao will lecture on the value of modeling and simulation for regulatory submission at University of Tokyo's Graduate School of Pharmaceutical Sciences
MOUNTAIN VIEW, Calif., March 13, 2006 /PRNewswire-FirstCall via COMTEX/ -- Pharsight Corporation (OTC Bulletin Board: PHST), a leading provider of software and strategic services for optimizing clinical drug development, announced today that Yuying Gao, M.D., Ph.D., Senior Scientist, will speak to members of the Japanese pharmaceutical industry attending the 28th mini-symposium of the Department of Molecular Pharmacokinetics, to be held at the University of Tokyo on March 23, 2006.
Dr. Gao will give a presentation on the strategic value of quantitative modeling and simulation to support regulatory submission, along with panelists from industry and academia, as part of a university-sponsored symposium entitled, "The Role of PK/PD Simulation in Drug Development: Is it Possible to Link the Simulation to the Regulatory Science?" The session will include applications of modeling and simulation to support key decisions, and will describe research on how "in silico" methods and technology have been used to predict pharmacokinetics in humans, treatment strategies, and drug-drug interactions. The session will also offer a forum for interdisciplinary discussion on the utility of model-based drug development in the drug approval process. Additional information can be found at http://www.f.u-tokyo.ac.jp/index-e.html.
Dr. Krause will give a presentation on conceptualized approaches and considerations for critical graphical analysis of clinical data, along with industry drug development professionals and technology experts, as part of an event entitled, "Transforming Data into a Graphical Output of Higher Value - Clinical Data Review & Reporting, Text & Data Mining, and Knowledge Management." The session will include case studies and applied examples in clinical drug development, and will also offer a forum for interdisciplinary discussion of quantitative methods and tools in the drug development process. Additional information can be found at: www.insightful.com/switzerland/us/news_events/basel06/default.asp.
Market Data 
Markets 
AI
